The global acute myeloid leukemia (AML) diagnostics market is driven by the increasing prevalence of AML, advancements in diagnostic technologies, and a growing emphasis on early and precise disease detection. The market is witnessing rapid innovation in molecular diagnostics, flow cytometry, immunophenotyping, and next-generation sequencing (NGS), enabling more accurate disease classification and personalized treatment approaches. Rising awareness, improvements in healthcare infrastructure, and increased investment in research and development further contribute to market growth. However, challenges such as high diagnostic costs, limited accessibility to advanced testing in developing regions, and the complexity of AML subtypes may hinder widespread adoption. North America leads the market due to strong healthcare infrastructure and high adoption rates of advanced diagnostics, while Asia-Pacific is emerging as a key growth region due to increasing healthcare expenditure and awareness. With ongoing advancements in precision medicine and biomarker-based testing, the AML diagnostics market is expected to evolve, offering improved patient outcomes through early and targeted disease management.
Global Acute Myeloid Leukemia Diagnostics Market is valued at USD 2.77 billion in 2023 and is expected to reach USD 6.53 billion by 2031, with a growing CAGR of 11.3% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-acute-myeloid-leukemia-diagnostics-market
Below are the Top Acute Myeloid Leukemia Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
CANON MEDICAL SYSTEMS CORPORATION
|
Canon Medical Systems Corporation is a subsidiary of Canon Inc. that specializes in medical imaging and diagnostic solutions. The company provides advanced imaging technologies, including ultrasound, CT, MRI, and nuclear medicine systems. In the context of AML diagnostics, Canon focuses on imaging techniques that can assist in the assessment of hematological malignancies, enhancing diagnostic accuracy and patient management. Their commitment to innovation and development of state-of-the-art imaging systems positions them as a key player in the diagnostics market.
|
Edition
Aquilion Prime SP
|
Asia, Europe, North America, Oceania, South America
|
In November, Canon Inc. acquired Redlen Technologies Inc. (Redlen), one of the world's leading companies in creating new technologies related to developing and manufacturing semiconductor detector modules. Canon Medical Systems Corporation (Canon Medical), a group company of Canon Inc., has developed the first domestically produced Photon-Counting CT (PCCT)3 system incorporating Redlen's advanced technologies. This system has been installed at the National Cancer Center (NCC) Exploratory Oncology Research & Clinical Trial Center in Japan, where it is currently used to conduct research exploring the clinical applications of PCCT.
|
|
2.
|
Sysmex Corporation
|
Sysmex Corporation is a global leader in laboratory diagnostics and healthcare solutions, particularly known for its hematology analyzers and diagnostic systems. The company develops advanced diagnostic tools for analyzing blood and bone marrow, which are crucial for diagnosing and monitoring AML. Sysmex's innovative technologies, including automated systems for cell analysis and molecular diagnostics, enhance the accuracy and efficiency of AML diagnostics, making them a significant contributor to the market.
|
Sysmex XT-2000i Automated Hematology Analyzer
|
America, Europe, Asia-Pacific
|
In October 2022, Sysmex Corporation Chairman and its CEO: Hisashi Ietsugu announced the approval, of an application for a partial change to the manufacturing and marketing approval in Japan of its gene amplification reagent LYNOAMP CK19 marketed as a lymph node metastasis test reagent for breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, expanding its amplification to cervical cancer and endometrial cancer.
|
|
3.
|
Epigenomics AG
|
Epigenomics AG is a molecular diagnostics company focused on developing cancer diagnostics based on DNA methylation technology. The company aims to provide innovative tests for early cancer detection, including tests for AML. Epigenomics' proprietary technology enables the identification of specific DNA methylation patterns associated with leukemia, facilitating earlier and more accurate diagnoses. Their research and development efforts contribute to advancements in AML diagnostics and personalized medicine.
|
|
North America, Europe
|
In September 2022, Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG, announced it had enrolled its first subject in a new pivotal clinical trial supporting the Company’s Next-Generation blood-based diagnostic screening test for the detection of colorectal cancer (CRC).
|
|
4.
|
MYRIAD GENETICS, INC.
|
Myriad Genetics, Inc. is a biotechnology company specializing in molecular diagnostics and personalized medicine. The company offers a range of diagnostic tests for various cancers, including tests that help assess the risk and presence of leukemia. Myriad's focus on genetic testing and biomarkers allows for more precise risk assessment and treatment strategies in AML patients. Their commitment to innovation and research in cancer diagnostics positions them as a key player in the market.
|
MyRisk Hereditary Cancer Test
|
North America, South America, Asia-Pacific, and Europe
|
In May 2022, Myriad Genetics, Inc. announced the company has expanded its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, that leads to new liquid biopsy therapy selection test additions in the company's growing oncology portfolio. This results in growing liquid biopsy space for the precise tumor test.
|
|
5.
|
F. HOFFMANN-LA ROCHE
|
F. Hoffmann-La Roche, commonly known as Roche, is a global leader in pharmaceuticals and diagnostics. Roche is well-known for its comprehensive portfolio of diagnostic solutions, including tests for hematological malignancies like AML. The company invests heavily in research and development to create innovative diagnostic assays and technologies, such as molecular tests and next-generation sequencing platforms. Roche's commitment to advancing cancer diagnostics and personalized treatment makes it a significant player in the AML diagnostics market.
|
Kits for PCR and immunoassays
|
Europe, Africa, America, Asia, Oceania,
|
In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics officially. With this acquisition, the company would also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation.
|
Conclusion
The global acute myeloid leukemia (AML) diagnostics market is positioned for robust growth, driven by the increasing incidence of AML and significant advancements in diagnostic technologies, including molecular diagnostics and next-generation sequencing. As healthcare systems emphasize the importance of early detection and personalized treatment, innovations in diagnostic methods are becoming pivotal in improving patient outcomes. While the market faces challenges such as high costs and accessibility issues, particularly in developing regions, the ongoing investment in research and development, along with a growing awareness of AML, presents substantial opportunities for growth. North America remains a leader in this market, but the Asia-Pacific region is poised to become a critical player as healthcare access improves. Overall, the AML diagnostics market is expected to continue evolving, enhancing early diagnosis and tailored treatment strategies for patients worldwide.
